Skip to Content
MoleculesMolecules
  • Review
  • Open Access

18 February 2022

An Update of the Sanguinarine and Benzophenanthridine Alkaloids’ Biosynthesis and Their Applications

,
,
and
Unidad de Bioquímica y Biología Molecular de Plantas, Centro de Investigación Científica de Yucatán, Calle 43 No. 130, Chuburná, Merida 97205, Mexico
*
Author to whom correspondence should be addressed.
This article belongs to the Special Issue Alkaloids in Future Drug Discovery

Abstract

Benzophenanthridines belong to the benzylisoquinolic alkaloids, representing one of the main groups of this class. These alkaloids include over 120 different compounds, mostly in plants from the Fumariaceae, Papaveraceae, and Rutaceae families, which confer chemical protection against pathogens and herbivores. Industrial uses of BZD include the production of environmentally friendly agrochemicals and livestock food supplements. However, although mainly considered toxic compounds, plants bearing them have been used in traditional medicine and their medical applications as antimicrobials, antiprotozoals, and cytotoxic agents have been envisioned. The biosynthetic pathways for some BZD have been established in different species, allowing for the isolation of the genes and enzymes involved. This knowledge has resulted in a better understanding of the process controlling their synthesis and an opening of the gates towards their exploitation by applying modern biotechnological approaches, such as synthetic biology. This review presents the new advances on BDZ biosynthesis and physiological roles. Industrial applications, mainly with pharmacological approaches, are also revised.

1. Introduction

Benzophenanthridines (BZD) represent one of the 11 classes of benzylisoquinoline alkaloids (BIA). BZD include over 120 alkaloids mainly spread in plants from the Fumariaceae, Papaveraceae, and Rutaceae families, within the Ranunculales and Sapindales orders [1]. Structurally, BZD are tetracyclic compounds, which include a non-aromatic heterocyclic system (B ring). Depending on the ring organization, BZD could be classified in three different groups: Type I (hexahydrobenzo[c]phenanthridines) includes two aromatic (A and D) and aliphatic (B and C) rings, in which the N atom in B is usually methylated. In BZD type II (dihydrobenzo[c]phenanthridines), the N atom is also methylated; however, ring B could be absent when the C7-C8 bond is open (type II-1) or modified with a complex substituent at C8 (type II-2). Regardless of ring B being absent, rings A, C, and D are aromatic systems. Finally, BDZ type III results from the N protonation of BDZ type I or II, leading to the corresponding ammonium quaternary salts (Figure 1) [2,3]. Depending on the chemical modifications within these basic structures, up to seven groups can be distinguished: hexahydrobenzophenanthridines (type I), seco-benzophenanthridines (type II-1), dimeric dihydrobenzophenanthridines (type II-2), N-demethylbenzophenanthridines, dihydrobenzophenanthridines, benzophenanthridones, and quaternary benzophenanthridine alkaloids (type III; Figure 1) [2,3].
Figure 1. Chemical structure of the different benzophenathridines (BZD).
Plants bearing BDZ have had important roles in human traditional medicine in both the old and new world cultures for centuries. For example, the great celandine (Chelidonium majus L.; Papaveraceae) was used by ancient Greeks to treat eye cataracts, whereas the fern leafed corydalis (Corydalis cheilanthifolia Helms; Fumarioideae/Papaveraceae) is mentioned in antique Chinese treatises for irregular menses. In the Americas, prior to Europeans’ arrival, the prickly poppy (Argemone mexicana L., Papaveraceae) was recommended to remove genital warts and for other skin infections [4]. Some of the alkaloids found in these plants are shown in Figure 2 and include sanguinarine (I) and its reduced dihydro form, dihydrosanguinarine (II), chelerythrine (III), cheilanthifoline (IV), corydine (V), corydaline (VI), and dehydrocorydaline (VII), among others. Table 1 lists some plant species that accumulate in BZD alkaloids as well as their different uses for medicinal purposes. There is an increasing interest in sanguinarine and other BZD alkaloids due to their diverse pharmacological effects and possible functions in plant–environment interactions. Here, a review of the new advances on the BDZ biosynthetic process and physiological roles is presented. Industrial applications, mainly with pharmacological approaches, are also revised.
Figure 2. Chemical structure of the BZD analyzed in this review.
Table 1. A few plants bearing BZD alkaloids and their traditional medicinal uses.

3. Concluding Remarks

In plants, BDZ alkaloids are part of an elaborated chemical defensive system sensitive to potentially harmful environmental stimuli, such as microbial infections and insect foraging. Interaction with these biological agents sets up a chain of biochemical events leading to the transcriptional activation of genes involved in their synthesis and mobilization [21,44,45,46,47]. The defensive role of secondary metabolites, such as alkaloids, in plants has turned into a valuable biotechnological tool, which is frequently used in in vitro cell cultures to increase their accumulation. Cell cultures submitted to conditions mimicking microbial infection or environmental hazards respond by increasing transcriptional activity, leading to the synthesis of these defensive compounds (the process is known as elicitation) [77]. Cell cultures from different species from the Papaveraceae family [42], including A. mexicana [78], E. californica [21], M. cordata [8], and P. somniferum [79], show this response when challenged by exposition to different stimuli. Besides its potential for commercial exploitation, elicitation has also allowed for the discovery of new enzymes [42,80] and has led to the design of ingenious approaches for chemical semisynthetic processes. For example, recently, an interest on BZD dihydro forms, mainly dihydrosanguinarine (II), has surged due to its minor cytotoxicity [81]. In plants, sanguinarine reductase (SanR; Figure 3) leads to the NADH-dependent reduction of sanguinarine and other BZD to the lesser toxic dihydro derivatives. This is part of a mechanism to avoid cell damages caused by an increase in the alkaloid accumulation in response to pathogen infection [21]. This response has instigated the development of a biomimetic approach for the reduction of the N7=C8 double-bond located in the B ring by incubating sanguinarine (I) with NADH under 455 nm blue radiation. This reaction produced a dihydrosanguinarine (II) dimer but also can be applied for the semi-synthesis of different natural substituted dihydroBZD [81]. In fact, an efficient total synthesis of selected BZD, such as chelerythrine (III) and sanguinarine (I), has been recently reported using affordable materials, such as 7-azabenzonorbornadiene and based on enzyme mechanisms [82]. However, although well-established at the cellular level, details on the operation of these mechanisms in integral tissues or the whole plant are yet to be discovered. Moreover, the complete biosynthetic pathway required for sanguinarine (I) and other BZD alkaloids has been isolated from different species [6,8,16,19], and some regulatory genes, and their corresponding cis-elements are also available [26,27]. This has allowed for dissecting which components of the pathway are responsive to specific biochemical mediators [45] and the mechanisms involved in this response. On the other hand, although still under observation due to undesirable side effects, the medical applications of sanguinarine (I) and related alkaloids is an area of intensive research (Table 3). Interestingly, BZD have been considered both cancerogenic and anticancer agents [83]. Epidemiological evidence links the use of mouthwashes added with sanguinarine to maxillary vestibule oral leukoplakia as well as its involuntary consumption in contaminated mustard oil to gall bladder [11,83]. However, different genotoxicity assays and animal tests for cancer genesis often deliver non-conclusive results. Therefore, neither sanguinarine (I) nor other BZD are currently listed as proved cancer-producing agents [83]. The BZD planar structure is similar to other polyaromatic hydrocarbon carcinogens that allow for intercalation in the DNA [2,3]. Besides, BZD induce cell oxidative burst with ROS formation. Paradoxically, although ROS accumulation triggered by BZD could cause DNA damage, it also could be the basis of their therapeutical application against cancer. This may be explained by the fact that a controlled increase in ROS could induce the activation of internal cell mechanisms directed to the mitigation of oxidative harm [58,59]. Moreover, sanguinarine and other BZD inhibited the P-glycoprotein/ABCB1 and related ABCB5 in drug resistance in multidrug-resistant tumor lines, increasing their sensitivity to cytotoxic drugs, which might allow for better treatments [84]. In this way, knowledge generated on the synthesis and regulation of these alkaloids could now be directed towards the generation of tools for their commercial exploitation by modern biotechnological methods, including cell culture technology and synthetic biology approaches. Scaling up for massive culture of elicited cell suspension has been reported [79] and the introduction of the complete sanguinarine (I) pathway to yeast cells has been recently achieved [85]. Moreover, the availability of the complete set of genes involved in sanguinarine (I) synthesis, as well as some of the regulatory genes and those involved in its mobilization, would allow for improving not only the enzymatic catalysis by gene edition but also the internal cell traffic of intermediaries, resulting in more efficient processes for the formation of these valuable alkaloids.

Author Contributions

Conceptualization, original draft preparation, review and editing, and project administration, F.V.-F.; review on biosynthesis and enzymes involved, J.I.L.-H.; review on tissue distribution and regulation, L.L.-M.; and review on uses and applications, J.A.M.-S. All authors have read and agreed to the published version of the manuscript.

Funding

This research study was funded by the National Council for Science and Technology (CONACyT; México), grant number CB-2016; 0285887. JIL-H and LL-M are recipients of the CONACYT scholarship for doctoral studies (815650 and 514907/289293, respectively).

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors thank M.L. Miranda-Ham for her critical review of this article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Singh, A.; Menéndez-Perdomo, I.M.; Facchini, P.J. Benzylisoquinoline alkaloid biosynthesis in opium poppy: An update. Phytochem. Rev. 2019, 18, 1457–1482. [Google Scholar] [CrossRef]
  2. Han, N.; Yang, Z.; Liu, Z.; Liu, H.; Yin, J. Research progress on natural benzophenanthridine alkaloids and their pharmacological functions: A review. Nat. Prod. Commun. 2016, 11, 1181–1188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Bisai, V.; Saina Shaheeda, M.K.; Gupta, A.; Bisai, A. Biosynthetic relationships and total syntheses of naturally occurring benzo [c] phenanthridine alkaloids. Asian J. Org. Chem. 2019, 8, 946–969. [Google Scholar] [CrossRef]
  4. Rubio-Piña, J.; Vazquez-Flota, F. Pharmaceutical applications of the benzylisoquinoline alkaloids from Argemone mexicana L. Curr. Top. Med. Chem. 2013, 13, 2200–2207. [Google Scholar] [CrossRef] [PubMed]
  5. Zielińska, S.; Jezierska-Domaradzka, A.; Wójciak-Kosior, M.; Sowa, I.; Junka, A.; Matkowski, A.M. Greater celandine’s ups and downs—21 centuries of medicinal uses of Chelidonium majus from the viewpoint of today’s pharmacology. Front. Pharmacol. 2018, 9, 299. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Liao, D.; Wang, P.; Jia, C.; Sun, P.; Qi, J.; Zhou, L.; Li, X. Identification and developmental expression profiling of putative alkaloid biosynthetic genes in Corydalis yanhusuo bulbs. Sci. Rep. 2016, 6, 1–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Zhang, J.; He, S.; Wang, J.; Wang, C.; Wu, J.; Wang, W.; Li, F.; Li, S.; Zhao, C.; Li, F. A Review of the traditional uses, botany, phytochemistry, pharmacology, pharmacokinetics, and toxicology of Corydalis yanhusuo. Nat. Prod. Commun. 2020, 15, 1934578X20957752. [Google Scholar]
  8. Liu, X.; Liu, Y.; Huang, P.; Ma, Y.; Qing, Z.; Tang, Q.; Cao, H.; Cheng, P.; Zheng, Y.; Yuan, Z.; et al. The genome of medicinal plant Macleaya cordata provides new insights into benzylisoquinoline alkaloids metabolism. Mol. Plant. 2017, 5, 975–989. [Google Scholar] [CrossRef] [Green Version]
  9. Rolland, A.; Fleurentin, J.; Lanhers, M.C.; Younos, C.; Misslin, R.; Mortier, F.; Pelt, J.M. Behavioural effects of the American traditional plant Eschscholzia californica: Sedative and anxiolytic properties. Planta Med. 1991, 57, 212–216. [Google Scholar] [CrossRef]
  10. Cahlíková, L.; Opletal, L.; Kurfürst, M.; Macáková, K.; Kulhánková, A.; Hošt’álková, A. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Chelidonium majus (Papaveraceae). Nat. Prod. Commun. 2010, 5, 1934578X1000501110. [Google Scholar] [CrossRef] [Green Version]
  11. Croaker, A.; King, G.J.; Pyne, J.H.; Anoopkumar-Dukie, S.; Liu, L. Sanguinaria canadensis: Traditional medicine, phytochemical composition, biological activities and current uses. Int. J. Mol. Sci. 2016, 17, 1414. [Google Scholar] [CrossRef] [Green Version]
  12. Samanani, N.; Facchini, P.J. Isolation and partial characterization of norcoclaurine synthase, the first committed step in benzylisoquinoline alkaloid biosynthesis, from opium poppy. Planta 2001, 213, 898–906. [Google Scholar] [CrossRef] [PubMed]
  13. Hagel, J.M.; Facchini, P.J. Benzylisoquinoine alkaloid metabolism: A century of discovery and a brave new world. Plant Cell Physiol. 2013, 54, 647–672. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Liscombe, D.K.; MacLeod, B.P.; Loukanina, N.; Nandi, O.I.; Facchini, P.J. Evidence for the monophyletic evolution of benzylisoquinoline alkaloid biosynthesis in angiosperms. Phytochemistry 2005, 66, 2501–2520. [Google Scholar] [CrossRef] [PubMed]
  15. Bastian, D.; Konrad, B.; Toplak, M.; Lahham, M.; Messenlehner, J.; Winkler, J.; Macheroux, P. The family of berberine bridge enzyme-like enzymes: A treasure-trove of oxidative reactions. Arch. Biochem. Biophys. 2017, 632, 88–103. [Google Scholar]
  16. Beaudoin, G.A.W.; Facchini, P.J. Benzylisoquinoline alkaloid biosynthesis in opium poppy. Planta 2014, 240, 19–32. [Google Scholar] [CrossRef] [Green Version]
  17. Díaz-Chávez, M.L.; Rolf, M.; Gesell, A.; Kutchan, T.M. Characterization of two methylenedioxy bridge-forming cytochrome P450-dependent enzymes of alkaloid formation in the Mexican prickly poppy Argemone mexicana. Arch. Biochem. Biophys. 2011, 507, 186–193. [Google Scholar] [CrossRef]
  18. Reed, J.W.; Hudlicky, T. The Quest for a practical synthesis of morphine alkaloids and their derivatives by chemoenzymatic methods. Acc. Chem. Res. 2015, 48, 674–687. [Google Scholar] [CrossRef]
  19. Yamada, Y.; Hirakawa, H.; Hori, K.; Minakuchi, Y.; Toyoda, A.; Shitan, N.; Sato, F. Comparative analysis using the draft genome sequence of California poppy (Eschscholzia californica) for exploring the candidate genes involved in benzylisoquinoline alkaloid biosynthesis. Biosci. Biotechnol. Biochem. 2021, 85, 851–859. [Google Scholar] [CrossRef]
  20. Loza-Muller, L.; Laines-Hidalgo, J.; Monforte-Gonzalez, M.; Vazquez-Flota, F. Alkaloid distribution in seeds of Argemone mexicana L. (Papaveraceae). J. Mex. Chem. Soc. 2021, 65, 4. [Google Scholar] [CrossRef]
  21. Weiss, D.; Baumert, A.; Vogel, M.; Roos, W. Sanguinarine reductase, a key enzyme of benzophenanthridine detoxification. Plant Cell Environ. 2006, 29, 291–302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Alcantara, J.; Bird, D.A.; Franceschi, V.R.; Facchini, P.J. Sanguinarine biosynthesis is associated with the endoplasmic reticulum in cultured opium poppy cells after elicitor treatment. Plant Physiol. 2005, 138, 173–183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Yu, X.; Gao, X.; Zhu, Z.; Cao, Y.; Zhang, Q.; Tu, P.; Chai, X. Alkaloids from the tribe Bocconieae (Papaveraceae): A chemical and biological review. Molecules 2014, 19, 13042–13060. [Google Scholar] [CrossRef] [Green Version]
  24. Nwanyichukwu, P. Identification and Characterization of an Adenosine Triphosphate Binding Cassette (ABC) Transporter Ecabcb1 Involved in the Transport of Alkaloids in Eschscholzia californica. Master’s Thesis, University of Calgary, Calgary, AB, Canada, 2014. [Google Scholar]
  25. Loza-Muller, L.; Shitan, N.; Yamada, Y.; Vázquez-Flota, F. AmABCB1, an alkaloid transporter from seeds of Argemone mexicana L. (Papaveraceae). Planta 2021, 254, 6. [Google Scholar] [CrossRef] [PubMed]
  26. Yamada, Y.; Motomura, Y.; Sato, F. CjbHLH1 homologs regulate sanguinarine biosynthesis in Eschscholzia californica cells. Plant Cell Physiol. 2015, 56, 1019–1030. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Yamada, Y.; Shimada, T.; Motomura, Y.; Sato, F. Modulation of benzylisoquinoline alkaloid biosynthesis by heterologous expression of CjWRKY in Eschscholzia californica cells. PLoS ONE 2017, 12, e0186963. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Salmore, A.K.; Hunter, M.D. Elevational trends in defense chemistry, vegetation, and reproduction in Sanguinaria canadensis. J. Chem. Ecol. 2001, 27, 1713–1727. [Google Scholar] [CrossRef]
  29. Liu, H.; Wang, J.; Zhao, J.; Lu, S.; Wang, J.; Jiang, W.; Ma, Z.; Zhou, L. Isoquinoline alkaloids from Macleaya cordata active against plant microbial pathogens. Nat. Prod. Commun. 2009, 4, 1934578X0900401120. [Google Scholar] [CrossRef] [Green Version]
  30. Singh, N.; Sharma, B. Toxicological effects of berberine and sanguinarine. Front. Mol. Biosci. 2018, 5, 21. [Google Scholar] [CrossRef] [Green Version]
  31. Schmeller, T.; Latz-Brüning, B.; Wink, M. Biochemical activities of berberine, palmatine and sanguinarine mediating chemical defense against microorganisms and herbivores. Phytochemistry 1997, 44, 257–266. [Google Scholar] [CrossRef]
  32. Wink, M.; Schmeller, T.; Latz-Bruning, B. Modes of action of allelochemical alkaloids: Interaction with neuroreceptors, DNA, and other molecular targets. J. Chem. Ecol. 1998, 24, 1881–1937. [Google Scholar] [CrossRef]
  33. Zou, C.; Wang, Y.; Zou, H.; Ding, N.; Geng, N.; Cao, C.; Zhang, G. Sanguinarine in Chelidonium majus induced antifeeding and larval lethality by suppressing food intake and digestive enzymes in Lymantria dispar. Pest. Biochem. Physiol. 2019, 153, 9–16. [Google Scholar] [CrossRef]
  34. Leger, E.A.; Forister, M.L. Increased resistance to generalist herbivores in invasive populations of the California poppy (Eschscholzia californica). Divers. Distrib. 2005, 11, 311–317. [Google Scholar] [CrossRef]
  35. Watts, S.M.; Dodson, C.D.; Reichman, O.J. The roots of defense: Plant resistance and tolerance to belowground herbivory. PLoS ONE 2011, 6, e18463. [Google Scholar] [CrossRef] [PubMed]
  36. Camacho-Tapia, M.; Sánchez-Soto, V.; Cámara Correia, K.; Pastirčáková, K.; Tovar-Pedraza, J.M. Powdery mildew of California poppy caused by Erysiphe eschscholziae in Mexico. Can. J. Plant. Pathol. 2018, 40, 461–466. [Google Scholar] [CrossRef]
  37. Park, M.J.; Cho, S.E.; Piątek, M.; Shin, H.D. First report of powdery mildew caused by Erysiphe macleayae on Macleaya microcarpa in Poland. Plant Dis. 2012, 96, 1376. [Google Scholar] [CrossRef]
  38. Zhou, L.; Huang, P.; Yu, L.; Zeng, J. First report of root rot caused by Fusarium oxysporum on Macleaya cordata in China. J. Plant Pathol. 2020, 102, 191–192. [Google Scholar] [CrossRef]
  39. O’Neill, N.R.; Jennings, J.C.; Bailey, B.A.; Farr, D.F. Dendryphion penicillatum and Pleospora papaveracea, destructive seedborne pathogens and potential mycoherbicides for Papaver somniferum. Phytopathology 2000, 90, 691–698. [Google Scholar] [CrossRef] [Green Version]
  40. Yang, X.J.; Miao, F.; Yao, Y.; Cao, F.J.; Yang, R.; Ma, Y.N.; Qin, B.-F.; Zhou, L. In vitro antifungal activity of sanguinarine and chelerythrine derivatives against phytopathogenic fungi. Molecules 2012, 17, 13026–13035. [Google Scholar] [CrossRef]
  41. Yang, R.; Gao, Z.F.; Zhao, J.Y.; Li, W.B.; Zhou, L.; Miao, F. New class of 2-Aryl-6-chloro-3, 4-dihydroisoquinolinium salts as potential antifungal agents for plant protection: Synthesis, bioactivity and structure–activity relationships. J. Agric. Food Chem. 2015, 63, 1906–1914. [Google Scholar] [CrossRef]
  42. Hagel, J.M.; Morris, J.S.; Lee, E.J.; Desgagné-Penix, I.; Bross, C.D.; Chang, L.; Chen, X.; Farrow, S.C.; Zhang, Y.; Soh, J.; et al. Transcriptome analysis of 20 taxonomically related benzylisoquinoline alkaloid-producing plants. BMC Plant Biol. 2015, 15, 227. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Trujillo-Villanueva, K.; Rubio-Piña, J.; Monforte-González, M.; Vázquez-Flota, F. Fusarium oxysporum homogenates and jasmonate induce limited sanguinarine accumulation in Argemone mexicana cell cultures. Biotechnol. Lett. 2010, 32, 1005–1009. [Google Scholar] [CrossRef] [PubMed]
  44. Guízar-González, C.; Monforte-González, M.; Vázquez-Flota, F. Yeast extract induction of sanguinarine biosynthesis is partially dependent on the octadecanoic acid pathway in cell cultures of Argemone mexicana L., the Mexican poppy. Biotechnol. Lett. 2016, 38, 1237–1242. [Google Scholar] [CrossRef] [PubMed]
  45. Färber, K.; Schumann, B.; Miersch, O.; Roos, W. Selective desensitization of jasmonate-and pH-dependent signaling in the induction of benzophenanthridine biosynthesis in cells of Eschscholzia californica. Phytochemistry 2003, 6, 491–500. [Google Scholar] [CrossRef]
  46. Roos, W.; Viehweger, K.; Dordschbal, B.; Schumann, B.; Evers, S.; Steighardt, J.; Schwartze, W. Intracellular pH signals in the induction of secondary pathways—The case of Eschscholzia californica. J. Plant Physiol. 2006, 163, 369–381. [Google Scholar] [CrossRef]
  47. Zhao, Z.M.; Shang, X.F.; Lawoe, R.K.; Liu, Y.Q.; Zhou, R.; Sun, Y.F.; Li, J.; Yang, G.Z.; Yang, C.J. Anti-phytopathogenic activity and the possible mechanisms of action of isoquinoline alkaloid sanguinarine. Pest. Biochem. Physiol. 2019, 159, 51–58. [Google Scholar] [CrossRef]
  48. Anjago, W.M.; Zeng, W.; Chen, Y.; Wang, Y.; Biregeya, J.; Li, Y.; Zhang, T.; Peng, M.; Yan, C.; Mingyue, S.; et al. The molecular mechanism underlying pathogenicity inhibition by sanguinarine in Magnaporthe oryzae. Pest. Manag. Sci. 2021, 77, 4669–4679. [Google Scholar] [CrossRef]
  49. Beuria, T.K.; Santra, M.K.; Panda, D. Sanguinarine blocks cytokinesis in bacteria by inhibiting FtsZ assembly and bundling. Biochemistry 2005, 44, 6584–16593. [Google Scholar] [CrossRef]
  50. Mingorance, J.; Rivas, G.; Vélez, M.; Gómez-Puertas, P.; Vicente, M. Strong FtsZ is with the force: Mechanisms to constrict bacteria. Trends Microbiol. 2008, 18, 348–356. [Google Scholar] [CrossRef]
  51. Tang, J.; Lebas, B.; Liefting, L.; Veerakone, S.; Wei, T.; Ward, L. Opium poppy mosaic virus, a new umbravirus isolated from Papaver somniferum in New Zealand. Arch. Virol. 2016, 161, 197–201. [Google Scholar] [CrossRef]
  52. Glasa, M.; Šoltys, K.; Predajňa, L.; Sihelská, N.; Nováková, S.; Šubr, Z.; Kraic, J.; Mihálik, D. Molecular and biological characterization of turnip mosaic virus isolates infecting poppy (Papaver somniferum and P. rhoeas) in Slovakia. Viruses 2018, 10, 430. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Dong, Z.; Liu, M.; Zhong, X.; Ou, X.; Yun, X.; Wang, M.; Ren, S.; Quing, Z.; Zeng, J. Identification of the impurities in Bopu Powder® and Sangrovit® by LC-MS combined with a screening method. Molecules 2021, 26, 3851. [Google Scholar] [CrossRef]
  54. Fu, Y.; Liu, W.; Liu, M.; Zhang, J.; Yang, M.; Wang, T.; Qian, W. In vitro anti-biofilm efficacy of sanguinarine against carbapenem-resistant Serratia marcescens. Biofouling 2021, 37, 341–351. [Google Scholar] [CrossRef] [PubMed]
  55. Zhang, Q.; Lyu, Y.; Huang, J.; Zhang, X.; Yu, N.; Wen, Z.; Chen, S. Antibacterial activity and mechanism of sanguinarine against Providencia rettgeri in vitro. PeerJ 2020, 8, e9543. [Google Scholar] [CrossRef] [PubMed]
  56. Fu, C.; Guan, G.; Wang, H. The anticancer effect of sanguinarine: A review. Curr. Pharm. Des. 2018, 24, 2760–2764. [Google Scholar] [CrossRef]
  57. Galadari, S.; Rahman, A.; Pallichankandy, S.; Thayyullathil, F. Molecular targets and anticancer potential of sanguinarine—A benzophenanthridine alkaloid. Phytomedicine 2017, 34, 143–153. [Google Scholar] [CrossRef]
  58. Khan, A.Q.; Rashid, K.; AlAmodi, A.A.; Agha, M.V.; Akhtar, S.; Hakeem, I.; Raza, S.S.; Uddin, S. Reactive oxygen species (ROS) in cancer pathogenesis and therapy: An update on the role of ROS in anticancer action of benzophenanthridine alkaloids. Biomed. Pharmacother. 2021, 143, 112142. [Google Scholar] [CrossRef]
  59. Akhtar, S.; Achkar, I.W.; Siveen, K.S.; Kuttikrishnan, S.; Prabhu, K.S.; Khan, A.Q.; Eiman, I.A.; Fairooz, S.; Jerobin, J.; Raza, A.; et al. Sanguinarine induces apoptosis pathway in multiple myeloma cell lines via inhibition of the JaK2/STAT3 signaling. Front. Oncol. 2019, 9, 285. [Google Scholar] [CrossRef] [Green Version]
  60. Perillo, B.; di Donato, M.; Pezone, A.; di Zazzo, E.; Giovannelli, P.; Galasso, G.; Castoira, G.; Migliaccio, A. ROS in cancer therapy: The bright side of the moon. Exp. Mol. Med. 2020, 52, 192–203. [Google Scholar] [CrossRef]
  61. Wang, Q.; Zhao, Z.; Shang, J.; Xia, W. Targets and candidate agents for type 2 diabetes treatment with computational bioinformatics approach. J. Diabetes Res. 2014, 763936. [Google Scholar] [CrossRef] [Green Version]
  62. Zhong, J. Sanguinarine ameliorates diabetic nephropathy in rats through nuclear factor-Kappa B and nuclear-factor erythroid 2-related factor 2/hemeoxygenase-1 pathways. Curr. Top. Nutraceutical Res. 2020, 19, 398–404. [Google Scholar]
  63. Falchi, F.A.; Borlotti, G.; Ferretti, F.; Pellegrino, G.; Raneri, M.; Schiavoni, M.; Caselli, A.; Briani, F. Sanguinarine inhibits the 2-ketoguconate pathway of glucose utilization in Pseudomonas aeruginosa. Front. Microbiol. 2021, 12, 744458. [Google Scholar] [CrossRef] [PubMed]
  64. Chang, Y.C.; Chang, F.R.; Khalil, A.T.; Hsieh, P.W.; Wu, Y.C. Cytotoxic benzophenanthridine and benzylisoquinoline alkaloids from Argemone mexicana. Z. Für Nat. C 2003, 58, 521–526. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Hazra, S.; Kumar, G.S. Structural and thermodynamic studies on the interaction of iminium and alkanolamine forms of sanguinarine with hemoglobin. J. Phys. Chem. B 2014, 118, 3771–3784. [Google Scholar] [CrossRef]
  66. Basu, P.; Kumar, G.S. Sanguinarine and its role in Chronic diseases. Adv. Exp. Med. Biol. 2016, 928, 155–172. [Google Scholar] [CrossRef]
  67. Zhang, F.; Mao, K.; Gu, Q.; Wu, W. The antiangiogenic effect of sanguinarine chloride on experimental chloroidal neovascularization in mice via inhibiting vascular endothelial growth factor. Front. Pharmacol. 2021, 15, 638215. [Google Scholar] [CrossRef]
  68. Choi, Y.H.; Choi, W.Y.; Hong, S.H.; Kim, S.O.; Kim, G.Y.; Lee, W.H.; Yoo, Y.H. Anti-invasive activity of sanguinarine through modulation of tight junctions and matrix metalloproteinase activities in MDA-MB-231 human breast carcinoma cells. Chem. Biol. Interact. 2009, 179, 185–191. [Google Scholar] [CrossRef]
  69. Choi, W.Y.; Jin, C.Y.; Han, M.H.; Kim, G.Y.; Kim, N.D.; Lee, W.H.; Kim, S.K.; Choi, Y.H. Sanguinarine sensitizes human gastric adenocarcinoma AGS cells to TRAIL-mediated apoptosis via down-regulation of AKT and activation of caspase-3. Anticancer Res. 2009, 29, 4457–4465. [Google Scholar]
  70. Achkar, I.W.; Mraiche, F.; Mohammed, R.M.; Uddin, S. anticancer potential of sanguinarine for various human malignancies. Future Med. Chem. 2017, 9, 933–950. [Google Scholar] [CrossRef]
  71. Niu, X.; Fan, T.; Li, W.; Xing, W.; Huang, H. The anti-inflammatory effects of sanguinarine and its modulation of inflammatory mediators from peritoneal macrophages. Eur. J. Pharmacol. 2012, 689, 262–269. [Google Scholar] [CrossRef]
  72. Mackraj, I.; Govender, T.; Gathiram, P. Sanguinarine. Cardiovasc. Drugs Rev. 2008, 26, 75–83. [Google Scholar] [CrossRef]
  73. Valipour, M.; Zarghi, A.; Ebrahimzadeh, M.A.; Irannejad, H. Therapeutic potential of chelerythrine as a multi-purpose adjuvant for the treatment of COVID-19. Cell Cycle 2021, 20, 2321–2336. [Google Scholar] [CrossRef] [PubMed]
  74. Chen, X.; Zhang, M.; Fan, P.; Qin, Y.; Zhao, H. Chelerythrine chloride induces apoptosis in renal cancer HEK-293 and SW-839 cell lines. Oncol. Lett. 2016, 11, 3917–3924. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Wangchuk, P.; Sastraruji, T.; Taweechotipatr, M.; Keller, P.; Pyne, S. Anti-inflammatory, Anti-bacterial and anti-acetylcholinesterase activities of two isoquinoline alkaloids-scoulerine and cheilanthifoline. Nat. Prod. Commun. 2016, 11, 1801–1804. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. He, N.; Wang, P.; Wang, P.; Ma, C.; Kang, W. Antibacterial mechanism of chelerythrine isolated from root of Toddalia asiatica (Linn) Lam. BMC Complement. Altern. Med. 2018, 18, 261. [Google Scholar] [CrossRef] [Green Version]
  77. Vázquez-Flota, F.A.; Loyola-Vargas, V.M. In vitro plant cell culture as the basis for the development of a Research Institute in México: Centro de Investigación Científica de Yucatán. In Vitro Cell. Dev. Biol. Plant 2003, 39, 250–258. [Google Scholar] [CrossRef]
  78. Xool-Tamayo, J.; Tamayo-Ordoñez, Y.; Monforte-González, M.; Muñoz-Sánchez, J.A.; Vázquez-Flota, F. Alkaloid biosynthesis in the early stages of the germination of Argemone mexicana L. (Papaveraceae). Plants 2021, 10, 2226. [Google Scholar] [CrossRef] [PubMed]
  79. Verma, P.; Khan, S.A.; Mathur, A.K.; Ghosh, S.; Shanker, K.; Kalra, A. Improved sanguinarine production via biotic and abiotic elicitations and precursor feeding in cell suspensions of latex-less variety of Papaver somniferum with their gene expression studies and upscaling in bioreactor. Protoplasma 2014, 251, 1359–1371. [Google Scholar] [CrossRef]
  80. Takemura, T.; Ikezawa, N.; Iwasa, K.; Sato, F. Molecular cloning and characterization of a cytochrome P450 in sanguinarine biosynthesis from Eschscholzia californica cells. Phytochemistry 2013, 91, 100–108. [Google Scholar] [CrossRef]
  81. Wang, L.; Wang, X.; Wang, W.; Liu, W.; Liu, Y.; Xie, H.; Reiser, O.; Zeng, J.; Cheng, P. Visible-light-promoted biomimetic reductive functionalization of quaternary benzophenanthridine alkaloids. J. Nat. Prod. 2021, 84, 2390–2397. [Google Scholar] [CrossRef]
  82. Aravindan, N.; Jeganmohan, M. A short total synthesis of benzophenanthridine alkaloids via a rhodium (III)-catalyzed C−H ring-opening reaction. J. Org. Chem. 2021, 86, 14826–14843. [Google Scholar] [CrossRef] [PubMed]
  83. Croaker, A.; Kinga, G.J.; Pyned, J.H.; Anoopkumar-Dukiec, S.; Simanekf, V.; Liua, L. Carcinogenic potential of sanguinarine. Mutat. Res. Rev. Mutat. Res. 2017, 774, 45–56. [Google Scholar]
  84. Saeed, M.E.; Mahmoud, N.; Sugimoto, Y.; Efferth, T.; Abdel-Aziz, H. Molecular determinants of sensitivity or resistance of cancer cells toward sanguinarine. Front. Pharmacol. 2018, 9, 136. [Google Scholar] [CrossRef] [PubMed]
  85. Fossati, E.; Ekins, A.; Narcross, L.; Zhu, Y.; Falgueyret, J.P.; Beaudoin, G.A.; Facchini, P.J.; Martin, V.J. Reconstitution of a 10-gene pathway for synthesis of the plant alkaloid dihydrosanguinarine in Saccharomyces cerevisiae. Nat. Commun. 2014, 5, 1–11. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.